http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4ec40fe00b1ea7e250733d004bc879f
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Bullmore |
| name | Edward T. Bullmore Edward T Bullmore |
| given-name | Edward T Edward T. |
| organization-name | Behavioural & Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0SZ, United Kingdom; Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom Department of Psychiatry, University of Cambridge, Cambridge, UK Department of Psychiatry, Cambridge and Peterborough Foundation Trust, University of Cambridge, Cambridge CB2 0SZ, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust Cambridge United Kingdom; Department of Psychiatry, Brain Mapping Unit University of Cambridge Cambridge United Kingdom Behavioural and Clinical Neuroscience Institute and Department of Experimental Psychology and Department of Psychiatry, University of Cambridge, Cambridge, CB2 3EB and CB2 0SZ, UK.; Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke’s Centre for Clinical Investigations, Cambridge CB2 2GG, UK.; Cambridgeshire and Peterborough Foundation, National Health Service Trust, Cambridge CB21 5EF, UK. Department of Psychiatry, Behavioural and Clinical Neurosciences Institute, University of Cambridge, UK; GlaxoSmithKline R&D, Stevenage UK, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge UK. Clinical Unit Cambridge, Medicines Discovery & Development GlaxoSmithKline R&D Cambridge UK; Brain Mapping Unit, Department of Psychiatry University of Cambridge UK Behavioural and Clinical Neuroscience Institute, University of Cambridge , Cambridge, CB2 3EB, UK; Wolfson Brain Imaging Centre, University of Cambridge, Addenbrooke’s Hospital , Cambridge CB2 0QQ, UK; Department of Psychiatry , , Cambridge CB2 0SZ, UK; University of Cambridge , , Cambridge CB2 0SZ, UK; Cambridgeshire & Peterborough NHS Foundation Trust , Cambridge CB21 5EF, UK Department of Psychiatry, University of Cambridge , Cambridge, UK Department of Psychiatry, University of Cambridge , Cambridge, UK; Cambridgeshire & Peterborough NHS Foundation Trust , Cambridge, UK; ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D , Stevenage, UK University of Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, UK; GlaxoSmithKline Research and Development, UK Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Department of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom Department of Psychiatry, University of Cambridge, Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK *Brain Mapping Unit, Department of Psychiatry, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 2QQ, United Kingdom; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom; Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom. Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Huntingdon, UK; Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK Behavioural and Clinical Neuroscience Institute Department of Psychiatry University of Cambridge Cambridge UK; Cambridgeshire and Peterborough NHS Foundation Trust Cambridge UK; ImmunoPsychiatry, Alternative Discovery and Development GlaxoSmithKline Cambridge UK Brain Mapping Unit, Department of Psychiatry University of Cambridge Cambridge UK; Cambridgeshire and Peterborough NHS Foundation Trust Cambridge UK Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB2 0SZ, United Kingdom;; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge CB21 5EF, United Kingdom; and; Clinical Unit Cambridge, GlaxoSmithKline, Cambridge CB2 0QQ, United Kingdom Medicines Discovery and Development, GlaxoSmithKline Clinical Unit, Cambridge, UK; Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, United Kingdom; Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge,United Kingdom. Department of Psychiatry, Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK; GlaxoSmithKline, Alternative Discovery and Development, Addenbrooke's Centre for Clinical Investigations, Cambridge, UK Department of Psychiatry University of Cambridge Cambridge UK; Research and Development Department Cambridgeshire and Peterborough National Health Service Foundation Trust Cambridge UK; Medical Research Council/Wellcome Trust Behavioural and Clinical Neuroscience Institute University of Cambridge Cambridge UK Department of Psychiatry, University of Cambridge, United Kingdom; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, United Kingdom; Medical Research Council/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom; ImmunoPsychiatry, GlaxoSmithKline Research and Development, Stevenage, United Kingdom Department of Psychiatry, University of Cambridge, Cambridge, CB2 0SZ, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Huntingdon, PE29 3RJ, UK; ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, SG1 2NY, UK. Section of Cognitive Psychopharmacology, Department of Psychological Medicine, and Department of Clinical Neurosciences, Institute of Psychiatry (King’s College), De Crespigny Park, London SE5 8AF, United Kingdom; and Department of Psychiatry, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 2QQ, United Kingdom Cambridgeshire and Peterborough NHS Foundation TrustCambridge United Kingdom; Brain Mapping UnitDepartment of PsychiatryUniversity of CambridgeCambridge United Kingdom; National Institute of Health Research, Cambridge Biomedical Research CentreCambridge United Kingdom; Behavioural and Clinical Neuroscience Institute, University of CambridgeCambridge United Kingdom Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Box 189, Cambridge CB2 0QQ, UK.; Behavioral and Clinical Neuroscience Institute (BCNI), University of Cambridge, Cambridge CB2 3EB, UK.; National OCD Treatment Service, Queen Elizabeth II Hospital, Welwyn Garden City AL7 4HQ, UK.; Medical Research Council (MRC) Cognition and Brain Sciences Unit, Cambridge CB2 7EF, UK.; Department of Experimental Psychology, University of Cambridge, Cambridge CB2 3EB, UK. Department of Psychiatry, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB2 0SZ, United Kingdom;; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge CB21 5EF, United Kingdom; and; GlaxoSmithKline Clinical Unit Cambridge, Addenbrookes Hospital, Cambridge CB2 0QQ, United Kingdom Medicines Discovery and Development GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke's Centre for Clinical Investigations Cambridge UK; Department of Psychiatry Behavioural and Clinical Neuroscience Institute, Cambridge Biomedical Campus, University of Cambridge Cambridge UK; Cambridgeshire and Peterborough NHS Foundation Trust (CPFT) Cambridge UK; Academic Discovery Performance Unit GlaxoSmithKline, Addenbrooke's Centre for Clinical Investigations Cambridge UK Brain Mapping Unit, Psychiatry Department, Cambridge University, Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Foundation Trust, Huntingdon, PE29 3RJ, UK; ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, SG1 2NY, UK Department of Psychiatry University of Cambridge Clinical School Cambridge UK Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK; Cambridgeshire & Peterborough NHS Foundation Trust, Huntingdon PE29 3RJ, UK; Immunology & Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB2 1QP, United Kingdom;; National Institute of Health Research Cambridge Biomedical Research Centre, Cambridgeshire Peterborough National Health System Foundation Trust, Cambridge SW1A 2NS, United Kingdom; and; Clinical Unit Cambridge, GlaxoSmithKline, Cambridge CB2 0QQ, United Kingdom Behavioural and Clinical Neuroscience Institute; Department of Psychology and Department of Psychiatry; University of Cambridge; UK; GlaxoSmithKline; Clinical Unit Cambridge; UK; Cambridgeshire and Peterborough NHS Foundation Trust; UK Brain Image Analysis Unit, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK Brain Mapping Unit, Department of Psychiatry University of Cambridge Cambridge United Kingdom Department of Psychiatry, University of Cambridge, Cambridge, UK; ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK Department of Psychiatry, Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge CB2 0SZ, United Kingdom;; Cambridgeshire & Peterborough National Health Service (NHS) Foundation Trust, Cambridge CB21 5EF, United Kingdom;; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, United Kingdom;; Immunopsychiatry, Alternative Discovery & Development, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom Department of Psychiatry, University of Cambridge; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, United Kingdom; ImmunoPsychiatry, GlaxoSmithKline, Stevenage, United Kingdom; Medical Research Council/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge Behavioural and Clinical Neuroscience Institute University of Cambridge UK; Department of Psychiatry University of Cambridge UK Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, United Kingdom. Cambridgeshire and Peterborough National Health Service Foundation Trust, United Kingdom. University of Cambridge, Department of Psychiatry, Cambridge CB2 0SZ, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Huntingdon PE29 3RJ, UK; ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK. Department of Psychiatry University of Cambridge UK 1University of Cambridge, United Kingdom Brain Mapping Unit and Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, United Kingdom.; Alternative Discovery and Development, GlaxoSmithKline, Cambridge, United Kingdom.; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom. Department of Psychiatry University of Cambridge Cambridge UK Brain Mapping Unit, Department of Psychiatry University of Cambridge Cambridge UK Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK; GlaxoSmithKline, GSK Ltd. Clinical Unit, Cambridge, UK Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, and; GlaxoSmithKline, Clinical Unit in Cambridge, Addenbrooke's Hospital, Cambridge; Departments of Psychiatry, Psychology, and Clinical Neurosciences and the Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, UK.; Immunopsychiatry Discovery Performance Unit, Alternative Discovery and Development Division, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK. Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, England Department of Psychiatry, University of Cambridge Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK; Behavioural and Clinical Neuroscience Institute (BCNI), University of Cambridge, Cambridge, UK; GlaxoSmithKline, Clinical Unit Cambridge, Addenbrooke's Centre for Clinical Investigations, Cambridge, UK Behavioural and Clinical Neurosciences Institute, Department of Psychiatry, University of Cambridge and; Clinical Unit Cambridge, GlaxoSmithKline, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom; Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Cambridge Biomedical Campus , Cambridge , UK Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, United Kingdom;; Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge CB21 5EF, United Kingdom; and; Clinical Unit Cambridge, Pharmaceutical Research and Development, GlaxoSmithKline, Cambridge CB2 0QQ, United Kingdom G. A. Calvert and S. D. Iversen, Departments of Psychiatry and Experimental Psychology, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK.; E. T. Bullmore, M. J. Brammer, S. C. R. Williams, P. K. McGuire, P. W. R. Woodruff, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5, 8AF UK.; R. Campbell, Department of Human Communication Science, University College London, Chandler House, 2 Wakefield Street, London WC1 1PG, UK.; A. S. David, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5, 8AF, and King’s College School of Medicine and Dentistry, 103 Denmark Hill, London SE5 8AZ, UK. Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, Cambridge CB2 3EB, United Kingdom;; Cambridgeshire and Peterborough NHS Foundation Trust, Huntingdon PE29 3RJ, United Kingdom;; Alternative Discovery and Development, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom |
Incoming Links
Total number of triples: 396.